Salma K. Jabbour

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +11

Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI

Ke Nie, Liming Shi, Qin Chen et al. · Clinical Cancer Research · 2016 · 427 citations · Full text

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

Matteo Palmeri, Janice M. Mehnert, Ann W. Silk et al. · ESMO Open · 2021 · 333 citations · Full text

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Salma K. Jabbour, Ki Hyeong Lee, Nikolaj Frost et al. · JAMA Oncology · 2021 · 231 citations · Full text

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe et al. · The Lancet Oncology · 2022 · 225 citations · Full text

Medicine, Previous Pd, Bronchial Neoplasm +5